2618 Federal Register / Vol. 89, No. 10 / Tuesday, January 16, 2024 / Notices 

data, training screeners, conducting the 

oral health screening at schools or Head 

Start sites. Screeners record four data 

points either electronically or on a 

paper form: (1) presence of treated 

caries; (2) presence of untreated tooth 

decay; (3) urgency of need for treatment; 

and (4) presence of dental sealants on at 

least one permanent molar tooth. 

State programs enter, clean and 

analyze the data; de-identify it; and 

respond to ASTDD’s annual email 

request for State-aggregated prevalence 

of dental caries and sealants. ASTDD 

reviews the data to ensure that both 

survey design and data meet specific 

criteria before sending it to CDC for 

publication on the CDC’s public-facing 

Oral Health Data website (www.cdc.gov/ 

oralhealthdata). 

BSS for children serves as a key State 

oral health surveillance data source and 

facilitates State capacity to: (1) monitor 

children’s oral health status, trends, and 

disparities, and compare with other 

States; (2) inform planning, 

implementation and evaluation of 

effective oral health programs and 

policies; (3) measure State progress 

toward Healthy People objectives; and 

(4) educate the public and policy 

makers regarding cross-cutting public 

health programs. CDC also uses the data 

to evaluate performance of CDC oral 

health funding recipients. 

The estimated total annualized 

burden hours for the survey across the 

34 States over the three years of this 

request are 40,207. There are no costs to 

children respondents other than their 

time. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total burden 

(in hours) 

Child ..................................... Screening form ................................................ 150,370 1 5/60 12,531 

Parent/caretaker .................. Consent ........................................................... 150,370 1 1/60 2,506 

Screener .............................. Screening form ................................................ 301 1 666/60 3,341 

School/site ........................... Participation form ............................................ 2,890 1 68/60 3,275 

State Official ........................ Data Submission form ..................................... 34 1 32,742/60 18,554 

Total .............................. .......................................................................... ........................ ........................ ...................... 40,207 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Public Health Ethics and 

Regulations, Office of Science, Centers for 

Disease Control and Prevention. 

[FR Doc. 2024–00654 Filed 1–12–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to 5 U.S.C. 1009(d), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended, and the Determination of 

the Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, CDC, pursuant to Public Law 

92–463. The grant applications and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Disease, Disability, 

and Injury Prevention and Control Special 

Emphasis Panel (SEP)–RFA–PS–24–039 

Improving the Quality of Life of People with 

HIV Aged 50 Years and Older in the United 

States, and RFA–PS–24–042 A Bridge to 

Adherence: Long-Acting Antiretroviral 

Therapy for People with HIV Released from 

Prison. 

Dates: May 1–2, 2024. 

Times: 10 a.m.–5 p.m., EDT. 

Place: Videoconference. 

Agenda: To review and evaluate grant 

applications. 

For Further Information Contact: 

Seraphine Pitt Barnes, Ph.D., M.P.H, 

C.H.E.S., Scientific Review Officer, National 

Center for HIV, Viral Hepatitis, STD, and TB 

Prevention, Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, Mailstop 

H24–6, Atlanta, Georgia 30329–4027. 

Telephone: (770) 488–6115; Email: 

SPittBarnes@cdc.gov. 

The Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention, has been delegated the authority 

to sign Federal Register notices pertaining to 

announcements of meetings and other 

committee management activities, for both 

the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2024–00676 Filed 1–12–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to 5 U.S.C. 1009(d), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended, and the Determination of 

the Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, CDC, pursuant to Public Law 

92–463. The grant applications and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Disease, Disability, 

and Injury Prevention and Control Special 

Emphasis Panel; (SEP)–RFA–IP–24–046, 

Nationwide Cohort to Estimate Burden of 

Respiratory Viruses and Immunologic 

Response (Blood Donor Cohort). 

Dates: April 11–12, 2024. 

Times: 10 a.m.–5 p.m., EDT. 

Place: Videoconference. 

Agenda: To review and evaluate grant 

applications. 

For Further Information Contact: Gregory 

Anderson, M.S., M.P.H, Scientific Review 

Officer, National Center for HIV, Viral 


ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 89, No. 10 / Tuesday, January 16, 2024 / Notices 2619 

Hepatitis, STD, and TB Prevention, Centers 

for Disease Control and Prevention, 1600 

Clifton Road NE, Mailstop H24–6, Atlanta, 

Georgia 30329–4027. Telephone: (404) 718– 

8833; Email: GAnderson@cdc.gov. 

The Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention, has been delegated the authority 

to sign Federal Register notices pertaining to 

announcements of meetings and other 

committee management activities, for both 

the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2024–00675 Filed 1–12–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[Docket No. CDC–2024–0001] 

Advisory Committee on Immunization 

Practices 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice and request for comment. 

SUMMARY: In accordance with regulatory 

provisions, the Centers for Disease 

Control and Prevention (CDC) 

announces the following meeting of the 

Advisory Committee on Immunization 

Practices (ACIP). This meeting is open 

to the public. Time will be available for 

public comment. 

DATES: The meeting will be held on 

February 28, 2024, from 8 a.m. to 5 p.m., 

EST and February 29, 2024, from 8 a.m. 

to 3 p.m., EST, (times subject to change; 

see the ACIP website for updates: 

https://www.cdc.gov/vaccines/acip/ 

index.html). 

Written comments must be received 

between February 1–22, 2024. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2024– 

0001, by either of the methods listed 

below. CDC does not accept comments 

by email. 

• Federal eRulemaking Portal: 

https://www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: Ms. Stephanie Thomas, ACIP 

Meeting, Centers for Disease Control 

and Prevention, 1600 Clifton Road NE, 

Mailstop H24–8, Atlanta, Georgia 

30329–4027. Attn: Docket No. CDC– 

2024–0001. 

Instructions: All submissions received 

must include the Agency name and 

docket number. All relevant comments 

received in conformance with the 

https://www.regulations.gov suitability 

policy will be posted without change to 

https://www.regulations.gov, including 

any personal information provided. For 

access to the docket to read background 

documents or comments received, go to 

https://www.regulations.gov. 

The meeting will be webcast live via 

the World Wide Web. The webcast link 

can be found on the ACIP website at 

https://www.cdc.gov/vaccines/acip/ 

index.html. 

FOR FURTHER INFORMATION CONTACT: 

Stephanie Thomas, Committee 

Management Specialist, Advisory 

Committee on Immunization Practices, 

National Center for Immunization and 

Respiratory Diseases, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, Mailstop H24–8, 

Atlanta, Georgia 30329–4027. 

Telephone: (404) 639–8836; Email: 

ACIP@cdc.gov. 

SUPPLEMENTARY INFORMATION: 

Purpose: The Advisory Committee on 

Immunization Practices (ACIP) is 

charged with advising the Director, 

Centers for Disease Control and 

Prevention (CDC), on the use of 

immunizing agents. In addition, under 

42 U.S.C. 1396s, the Committee is 

mandated to establish and periodically 

review and, as appropriate, revise the 

list of vaccines for administration to 

vaccine-eligible children through the 

Vaccines for Children program, along 

with schedules regarding dosing 

interval, dosage, and contraindications 

to administration of vaccines. Further, 

under applicable provisions of the 

Affordable Care Act and section 2713 of 

the Public Health Service Act, 

immunization recommendations of 

ACIP that have been approved by the 

Director, CDC, and appear on CDC 

immunization schedules generally must 

be covered by applicable health plans. 

Matters To Be Considered: The agenda 

will include discussions on influenza 

vaccines, chikungunya vaccine, COVID– 

19 vaccines, meningococcal vaccines, 

pneumococcal vaccines, polio vaccines, 

Human papillomavirus (HPV) vaccines, 

respiratory syncytial virus vaccines, a 

combined Diphtheria and Tetanus 

Toxoids and Acellular Pertussis, 

Inactivated Poliovirus, Haemophilus 

influenzae Type B Conjugate, and 

Hepatitis B vaccine (Vaxelis®), and 

vaccines to prevent diphtheria, tetanus, 

and pertussis. Recommendation votes 

are scheduled for influenza vaccines, 

COVID–19 vaccines, and chikungunya 

vaccine. A Vaccines for Children (VFC) 

vote is scheduled for vaccines to 

prevent diphtheria, tetanus, and 

pertussis. Agenda items are subject to 

change as priorities dictate. For more 

information on the meeting agenda, visit 

https://www.cdc.gov/vaccines/acip/ 

meetings/index.html. 

Meeting Information: The meeting 

will be webcast live via the World Wide 

Web. For more information on ACIP, 

please visit the ACIP website: https://

www.cdc.gov/vaccines/acip/index.html. 

Public Participation 

Interested persons or organizations 

are invited to participate by submitting 

written views, recommendations, and 

data. Please note that comments 

received, including attachments and 

other supporting materials, are part of 

the public record and are subject to 

public disclosure. Comments will be 

posted on https://www.regulations.gov. 

Therefore, do not include any 

information in your comment or 

supporting materials that you consider 

confidential or inappropriate for public 

disclosure. If you include your name, 

contact information, or other 

information that identifies you in the 

body of your comments, that 

information will be on public display. 

CDC will review all submissions and 

may choose to redact, or withhold, 

submissions containing private or 

proprietary information such as Social 

Security numbers, medical information, 

inappropriate language, or duplicate/ 

near-duplicate examples of a mass-mail 

campaign. CDC will carefully consider 

all comments submitted into the docket. 

Written Public Comment: The docket 

will be opened to receive written 

comments on February 1–22, 2024. 

Written comments must be received by 

February 22, 2024. 

Oral Public Comment: This meeting 

will include time for members of the 

public to make an oral comment. Oral 

public comment will occur before any 

scheduled votes, including all votes 

relevant to the ACIP’s Affordable Care 

Act and Vaccines for Children Program 

roles. Priority will be given to 

individuals who submit a request to 

make an oral public comment before the 

meeting according to the procedures 

below. 

Procedure for Oral Public Comment: 

All persons interested in making an oral 

public comment at the February 28–29, 

2024, ACIP meeting must submit a 

request at https://www.cdc.gov/ 

vaccines/acip/meetings/index.html 

between February 1, 2024, and no later 

than 11:59 p.m., EST, February 22, 

2024, according to the instructions 

provided. 


ddrumheller on DSK120RN23PROD with NOTICES1